Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 11, 2015, Pages 935-944

  Bhalla, Shaifali ^a   Pais, Gwendolyn ^a   Tapia, Melissa ^a   Gulati, Anil ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Endothelin A receptor antagonist BQ123; Morphine; Nerve growth factor (NGF); Oxycodone; Vascular endothelial growth factor (VEGF); Withdrawal

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MORPHINE SULFATE; NALOXONE; NERVE GROWTH FACTOR; OXYCODONE; VASCULOTROPIN; CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN A RECEPTOR ANTAGONIST; NARCOTIC ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT DISORDER; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HYPOTHERMIA; JUMPING; MALE; MORPHINE TOLERANCE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; TREATMENT RESPONSE; WESTERN BLOTTING; WET DOG SHAKES; WITHDRAWAL SYNDROME; ANIMAL; DRUG EFFECTS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; ENDOTHELIN A RECEPTOR ANTAGONISTS; MALE; MICE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PEPTIDES, CYCLIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84945394895     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0022     Document Type: Article

References (65)

1. Airaksinen, M.S., and Saarma, M. 2002. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3(5): 383-394. doi:10.1038/nrn812. PMID:11988777.
2. Akbarian, S., Rios, M., Liu, R.J., Gold, S.J., Fong, H.F., Zeiler, S., et al. 2002. Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J. Neurosci. 22(10): 4153-4162. PMID:12019333.
3. Aloe, L., Bracci-Laudiero, L., Alleva, E., Lambiase, A., Micera, A., and Tirassa, P. 1994. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 91(22): 10440-10444. doi:10.1073/pnas.91.22.10440. PMID:7937971.
4. Amato, L., Davoli, M., Perucci, C.A., Ferri, M., Faggiano, F., and Mattick, R.P. 2005. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 28(4): 321-329. doi:10.1016/j.jsat.2005.02.007. PMID:15925266.
5. Bhalla, S., Matwyshyn, G., and Gulati, A. 2002. Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides, 23(10): 1837-1845. doi:10.1016/S0196-9781(02)00141-9. PMID:12383872.
6. Bhalla, S., Matwyshyn, G., and Gulati, A. 2003. Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides, 24(4): 553-561. doi:10.1016/S0196-9781(03)00110-4. PMID:12860199.
7. Bhalla, S., Matwyshyn, G., and Gulati, A. 2004. Central endothelin-B receptor stimulation does not affect morphine analgesia in rats. Pharmacology, 72(1): 20-25. doi:10.1159/000078628. PMID:15292651.
8. Bhalla, S., Matwyshyn, G., and Gulati, A. 2005. Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists. Brain Res. 1064(1-2): 126-135. doi:10.1016/j.brainres.2005.09.054. PMID:16289404.
9. Bhalla, S., Zhang, Z., Patterson, N., and Gulati, A. 2010. Effect of endothelin-A receptor antagonist on mu, delta and kappa opioid receptor-mediated antinociception in mice. Eur. J. Pharmacol. 635(1-3): 62-71. doi:10.1016/j.ejphar.2010.03.003. PMID:20303944.
10. Bie, B., Wang, Y., Cai, Y.Q., Zhang, Z., Hou, Y.Y., and Pan, Z.Z. 2012. Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward. Neuropsychopharmacology, 37(13): 2780-2788. doi:10.1038/npp.2012.144. PMID:22871918.
11. Blebea, J., Mazo, J.E., Kihara, T.K., Vu, J.H., McLaughlin, P.J., Atnip, R.G., and Zagon, I.S. 2000. Opioid growth factor modulates angiogenesis. J. Vasc. Surg. 32(2): 364-373. doi:10.1067/mva.2000.107763b. PMID:10917997.
12. Blumberg, H.P., Wang, F., Chepenik, L.G., Kalmar, J.H., Edmiston, E., Duman, R.S., and Gelernter, J. 2008. Influence of vascular endothelial growth factor variation on human hippocampus morphology. Biol. Psychiatry, 64(10): 901-903. doi:10.1016/j.biopsych.2008.07.003. PMID:18707678.
13. Bolanos, C.A., and Nestler, E.J. 2004. Neurotrophic mechanisms in drug addiction. Neuromolecular Med. 5(1): 69-83. doi:10.1385/NMM:5:1:069. PMID: 15001814.
14. Bruns, M.B., and Miller, M.W. 2007. Functional nerve growth factor and trkA autocrine/paracrine circuits in adult rat cortex are revealed by episodic ethanol exposure and withdrawal. J. Neurochem. 100(5): 1155-1168. doi:10.1111/j.1471-4159.2006.04301.x. PMID:17316397.
15. Brunstein, C.G., Barker, J.N., Weisdorf, D.J., DeFor, T.E., Miller, J.S., Blazar, B.R., et al. 2007. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood, 110(8): 3064-3070. doi:10.1182/blood-2007-04-067215. PMID:17569820.
16. Cahill, C.M., Dray, A., and Coderre, T.J. 2003. Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology, 45(4): 543-552. doi:10.1016/S0028-3908(03)00192-8. PMID: 12907315.
17. Calza, L., Giardino, L., Giuliani, A., Aloe, L., and Levi-Montalcini, R. 2001. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc. Natl. Acad. Sci. U.S.A. 98(7): 4160-4165. doi:10.1073/pnas.051626998. PMID:11259645.
18. Cedarbaum, J.M., and Aghajanian, G.K. 1977. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur. J. Pharmacol. 44(4): 375-385. doi:10.1016/0014-2999(77)90312-0. PMID:330174.
19. Cirulli, F., Alleva, E., Antonelli, A., and Aloe, L. 2000. NGF expression in the developing rat brain: effects of maternal separation. Brain Res. Dev. Brain Res. 123(2): 129-134. doi:10.1016/S0006-8993(00)02844-4. PMID:11042341.
20. D’Amour, F.E., and Smith, D.L. 1941. A method of determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72: 74-79.
21. Doyon, S. 2004. Opioids. In Emergency Medicine: A Comprehensive Study Guide. Edited by J.E. Tintinalli, G.D. Kelen, J.S. Stapczynski, O.J. Ma, and D.M. Cline. McGraw-Hill, New York, N.Y.
22. Fiellin, D.A., Schottenfeld, R.S., Cutter, C.J., Moore, B.A., Barry, D.T., and O’Connor, P.G. 2014. Primary care-based buprenorphine taper vs mainte-nance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Intern. Med. 174(12): 1947-1954. doi:10.1001/jamainternmed.2014.5302. PMID:25330017.
23. Gold, M.S., Redmond, D.E., Jr., and Kleber, H.D. 1978. Clonidine blocks acute opiate-withdrawal symptoms. Lancet, 2(8090): 599-602. doi:10.1016/S0140-6736(78)92823-4. PMID:80526.
24. Gomaa, A.A., Moustafa, S.A., and Farghali, A.A. 1989. Adenosine triphosphate blocks opiate withdrawal symptoms in rats and mice. Pharmacol. Toxicol. 64(1): 111-115. doi:10.1111/j.1600-0773.1989.tb00611.x. PMID:2755901.
25. Gomes, C., Svensson, T.H., and Trolin, G. 1976. Effects of morphine on central catecholamine turnover, blood pressure and heart rate in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 294(2): 141-147. doi:10.1007/BF00507846. PMID:1012334.
26. Gormanns, P., Mueller, N.S., Ditzen, C., Wolf, S., Holsboer, F., and Turck, C.W. 2011. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J. Psychiatr. Res. 45(7): 973-979. doi:10.1016/j.jpsychires.2010.12.010. PMID:21255794.
27. Guillon, C.D., Koppel, G.A., Brownstein, M.J., Chaney, M.O., Ferris, C.F., Lu, S.F., et al. 2007. Azetidinones as vasopressin V1a antagonists. Bioorg. Med. Chem. 15(5): 2054-2080. doi:10.1016/j.bmc.2006.12.031. PMID:17234419.
28. Gulati, A., Kumar, A., Morrison, S., and Shahani, B.T. 1997a. Effect of centrally administered endothelin agonists on systemic and regional blood circulation in the rat: role of sympathetic nervous system. Neuropeptides, 31(4): 301-309. doi:10.1016/S0143-4179(97)90063-9. PMID:9308015.
29. Gulati, A., Rebello, S., and Kumar, A. 1997b. Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am. J. Physiol. 273(3): H1177-H1186. PMID:9321804.
30. Hatami, H., Oryan, S., Semnanian, S., Kazemi, B., Bandepour, M., and Ahmadiani, A. 2007. Alterations of BDNF and NT-3 genes expression in the nucleus paragigantocellularis during morphine dependency and withdrawal. Neuropeptides, 41(5): 321-328. doi:10.1016/j.npep.2007.04.007. PMID: 17688944.
31. Heberlein, A., Bleich, S., Bayerlein, K., Frieling, H., Groschl, M., Kornhuber, J., and Hillemacher, T. 2008. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 33(7): 999-1003. doi:10.1016/j.psyneuen.2008.05.011. PMID:18639986.
32. Heberlein, A., Dursteler-MacFarland, K.M., Frieling, H., Groschl, M., Lenz, B., Bonsch, D., et al. 2012. Association of nerve growth factor and vascular endothelial growth factor A with psychometric measurements of opiate dependence: results of a pilot study in patients participating in a structured diamorphine maintenance program. Eur. Addict. Res. 18(5): 213-219. doi:10.1159/000337212. PMID:22517242.
33. Heberlein, A., Muschler, M., Frieling, H., Behr, M., Eberlein, C., Wilhelm, J., et al. 2013. Epigenetic down regulation of nerve growth factor during alcohol withdrawal. Addict. Biol. 18(3): 508-510. doi:10.1111/j.1369-1600.2010.00307.x. PMID:21392176.
34. Himmelsbach, C.K. 1937. Clinical studies of drug addiction-II. “Rossium” treatment of drug addiction. Public Health Reports (Supp 125).
35. Jackson, T.P., Lonergan, D.F., Todd, R.D., and Martin, P.R. 2013. Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome. Pain Pract. 13(4): 297-309. doi: 10.1111/j.1533-2500.2012.00584.x. PMID:22925591.
36. Kosten, T.R., and George, T.P. 2002. The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 1(1): 13-20. doi:10.1151/spp021113. PMID:18567959.
37. Krantz, M.J., and Mehler, P.S. 2004. Treating opioid dependence. Growing implications for primary care. Arch. Intern. Med. 164(3): 277-288. doi:10.1001/ archinte.164.3.277. PMID:14769623.
38. Kreek, M.J., and Koob, G.F. 1998. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51(1-2): 23-47. doi:10.1016/ S0376-8716(98)00064-7. PMID:9716928.
39. Leonard, M.G., and Gulati, A. 2013. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res. 1528: 28-41. doi:10.1016/j.brainres.2013.07.002. PMID:23850649.
40. Leonard, M.G., Briyal, S., and Gulati, A. 2011. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res. 1420: 48-58. doi:10.1016/j.brainres.2011.08.075. PMID:21959172.
41. Lewis, M.J., Costa, J.L., Jacobowitz, D.M., and Margules, D.L. 1976. Tolerance, physical dependence and opiod-seeking behavior: dependence of diencephalic norepinephrine. Brain Res. 107(1): 156-165. doi:10.1016/0006-8993(76)90105-0. PMID:944611.
42. Ling, W., Amass, L., Shoptaw, S., Annon, J.J., Hillhouse, M., Babcock, D., et al. 2005. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100(8): 1090-1100. doi:10.1111/j.1360-0443.2005.01154.x. PMID:16042639.
43. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193(1): 265-275. PMID: 14907713.
44. Martin, J.R., and Takemori, A.E. 1987. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity. J. Pharmacol. Exp. Ther. 241(1): 48-55. PMID:3572795.
45. Martin, W.R., and Jasinski, D.R. 1969. Physiological parameters of morphine dependence in man-tolerance, early abstinence, protracted abstinence. J. Psychiatr. Res. 7(1): 9-17. doi:10.1016/0022-3956(69)90007-7. PMID:5352850.
46. Moore, R.Y., and Bloom, F.E. 1979. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2: 113-168. doi:10.1146/annurev.ne.02.030179.000553. PMID: 231924.
47. Numan, S., Lane-Ladd, S.B., Zhang, L., Lundgren, K.H., Russell, D.S., Seroogy, K.B., and Nestler, E.J. 1998. Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal. J. Neurosci. 18(24): 10700-10708. PMID:9852605.
48. Ozdogan, U.K., Lahdesmaki, J., and Scheinin, M. 2003. Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. Eur. J. Pharmacol. 460(2-3): 127-134. doi:10.1016/S0014-2999(02)02961-8. PMID: 12559372.
49. Paredes, D., Granholm, A.C., and Bickford, P.C. 2007. Effects of NGF and BDNF on baseline glutamate and dopamine release in the hippocampal formation of the adult rat. Brain Res. 1141: 56-64. doi:10.1016/j.brainres.2007.01.018. PMID: 17292337.
50. Pasternak, G.W. 2001. The pharmacology of mu analgesics: from patients to genes. Neuroscientist, 7(3): 220-231. doi:10.1177/107385840100700307. PMID: 11499401.
51. Peckham, E.M., and Traynor, J.R. 2006. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 316(3): 1195-1201. doi:10.1124/jpet.105.094276. PMID:16291875.
52. Raisch, D.W., Fudala, P.J., Saxon, A.J., Walsh, R., Casadonte, P., Ling, W., et al. 2005. Pharmacists’ and technicians’ perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J. Am. Pharm. Assoc. (2003), 45(1): 23-32. doi:10.1331/1544345052843200. PMID:15730114.
53. Ramesh, D., Ross, G.R., Schlosburg, J.E., Owens, R.A., Abdullah, R.A., Kinsey, S.G., et al. 2011. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J. Pharmacol. Exp. Ther. 339(1): 173-185. doi:10.1124/jpet.111.181370. PMID:21719468.
54. Redmond, D.E., Jr. 1977. Animal Models in Psychiatry and Neurology. Oxford. p. 293.
55. Rehni, A.K., Jaggi, A.S., and Singh, N. 2013. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol. Disord. Drug Targets, 12(1): 112-125. doi:10.2174/1871527311312010017. PMID:23244430.
56. Schug, S.A., Zech, D., and Grond, S. 1992. Adverse effects of systemic opioid analgesics. Drug Saf. 7(3): 200-213. doi:10.2165/00002018-199207030-00005. PMID:1354445.
57. Simchon-Tenenbaum, Y., Weizman, A., and Rehavi, M. 2015. Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Behav. Brain Res. 282: 125-132. doi:10.1016/j.bbr.2014.12.058. PMID:25576963.
58. Simoens, S., Matheson, C., Bond, C., Inkster, K., and Ludbrook, A. 2005. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br. J. Gen. Pract. 55(511): 139-146. PMID:15720937.
59. Smith, M.A., and Yancey, D.L. 2003. Sensitivity to the effects of opioids in rats with free access to exercise wheels: mu-opioid tolerance and physical dependence. Psychopharmacology (Berl.), 168(4): 426-434. doi:10.1007/s00213-003-1471-5. PMID:12709780.
60. Svensson, T.H., Bunney, B.S., and Aghajanian, G.K. 1975. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 92(2): 291-306. doi:10.1016/0006-8993(75)90276-0. PMID:1174954.
61. Tseng, L.F., Loh, H.H., and Wei, E.T. 1975. Effects of clonidine on morphine withdrawal signs in the rat. Eur. J. Pharmacol. 30(1): 93-99. doi:10.1016/0014-2999(75)90208-3. PMID:1168138.
62. Vargas-Perez, H., Ting, A.K.R., and van der Kooy, D. 2009a. Different neural systems mediate morphine reward and its spontaneous withdrawal aversion. Eur. J. Neurosci. 29(10): 2029-2034. doi:10.1111/j.1460-9568.2009.06749.x. PMID:19453632.
63. Vargas-Perez, H., Ting, A.K.R., Walton, C.H., Hansen, D.M., Razavi, R., Clarke, L., et al. 2009b. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science, 324(5935): 1732-1734. doi:10.1126/science.1168501. PMID:19478142.
64. Way, E.L., Loh, H.H., and Shen, F.H. 1969. Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther. 167(1): 1-8. PMID:5814495.
65. Williams, J.T., Christie, M.J., and Manzoni, O. 2001. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81(1): 299-343. PMID: 11152760.